Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
C-MYC rearrangement has been listed as a new subcategory of B-cell acute lymphoblastic leukemia (B-ALL) in the latest International Consensus Classification (ICC), but B-cell lymphoblastic lymphoma (B-LBL) with C-MYC rearrangement is extremely rare and therefore is a novel finding worth reporting. In this study, we described a small number of pediatric cases of B-LBL with C-MYC rearrangement, which overlapped features of B-LBL and Burkitt lymphoma (BL), including highly aggressive clinical presentation, lymphoblasts with precursor B-cell phenotype and C-MYC rearrangement; the combination treatment of the mature B-NHL protocol and ALL-type protocol may be appropriate for this rare entity, and more studies are required to identify an adequate therapeutic strategy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141392 | PMC |
| http://dx.doi.org/10.1007/s00277-025-06330-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Atypical clinicopathological features of monomorphic epitheliotropic intestinal T-cell lymphoma].
Zhonghua Xue Ye Xue Za Zhi
July 2025
Department of Pathology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
This study sought to examine the clinicopathological features of monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) and to discuss its differential diagnosis. A total of 36 MEITL cases, collected between June 2015 and January 2024 from the Fourth Affiliated Hospital of Soochow University and the First Affiliated Hospital, College of Medicine, Zhejiang University, were analyzed. Patients underwent immunohistochemistry, in situ hybridization for Epstein-Barr virus-encoded small RNA (EBER), and T-cell receptor (TCR) gene rearrangement testing.
View Article and Find Full Text PDFExploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)-rearranged acute leukaemia.
Br J Pharmacol
August 2025
School of Life and Health Sciences, University of Roehampton, London, UK.
Background And Purpose: Activation of Protein Phosphatase 2A (PP2A), via genetic and pharmacologic modulation of SET, has recently being identified as a promising strategy to therapeutically target acute myeloid leukaemia (AML) carrying KMT2A (MLL) chromosomal translocations (KMT2A-r AML).
Experimental Approach: In this study, we investigated the expression of PP2A subunits and the therapeutic potential of forskolin, a cyclic adenosine monophosphate (cAMP) elevating natural compound that has been reported as a PP2A activator.
Key Results: Our data show that PPP2CA encoding protein phosphatase 2 catalytic subunit α is abundantly expressed in KMT2A-r AML cells.
Primary central nervous system lymphomas in three "blue books" and correlation of recently defined primary large B-cell lymphoma of immune-privileged sites: Single-center experience.
Indian J Pathol Microbiol
August 2025
Department of Pathology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.
Background And Objectives: Primary central nervous system lymphomas (PCNSLs) are extranodal non-Hodgkin lymphomas confined to the brain, leptomeninges, eyes, or spinal cord without systemic involvement. The main goal of this study is to examine the incorporation of PCNSLs in three distinct "blue books" (WHO Classification of CNS Tumors [WHO-CNS5], WHO Classification of Hematopoietic and Lymphoid Tissues, Revised 4th edition [WHO-HAEM4R], WHO Classification of Hematolymphoid Tumors, 5th edition [beta version] [WHO-HAEM5-Beta]).
Materials And Methods: Fifteen immunocompetent patients diagnosed with PCNSL between 2016 and 2023 were included in this study.
Chidamide and anlotinib synergistically inhibit high grade B-cell lymphomas via PI3K/AKT signaling pathway.
Sci Rep
August 2025
Department of Hematology, The First Affiliated Hospital of Xiamen University andInstitute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, China.
High-grade B-cell lymphoma with concurrent MYC and BCL2/BCL6 rearrangements (HGBL-DHL) is a challenging disease resistant to front-line immunochemotherapies, which urgently requires novel therapeutic approaches. Herein, combination of chidamide and anlotinib demonstrated potential synergistic anti-lymphoma effects against HGBL-DHL. The cooperative effect of cell proliferation inhibition, apoptosis induction, and cell cycle arrest were demonstrated in cell lines through Cell Counting Kit-8, Annexin V/PI staining, and PI staining respectively.
View Article and Find Full Text PDFGenomic characterization of clonal B-cell lymphocytosis of marginal zone origin with MYC rearrangements.
Virchows Arch
July 2025
Pathology Department, Molecular Cytogenetics, Molecular Diagnostic and Hematological Cytology Laboratories, Hospital del Mar, Barcelona, Spain.
Monoclonal B-cell lymphocytosis of marginal zone origin (MBL-MZ) is an indolent clonal disorder with potential progression to lymphoma. MYC rearrangements (MYCr), typically linked to aggressive B-cell lymphomas, have not been reported in MBL-MZ. We describe three MBL-MZ cases with MYCr and TP53 alterations, detected via karyotyping, FISH, and optical genome mapping.
View Article and Find Full Text PDF